Pancreatic Cancer Research

ResearcherDuke UniversityActive in the last 2 years

Manisha Palta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9085-9075; OpenAlex author ID A5019376688. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  2. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  3. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.11.017↗
  4. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  5. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
  6. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  7. A current perspective on stereotactic body radiation therapy for pancreatic cancer. Last author DOI 10.2147/ott.s99826↗
  8. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. Last author DOI 10.3978/j.issn.2078-6891.2015.014↗
  9. The role of intraoperative radiation therapy in patients with pancreatic cancer. Co-author DOI 10.1016/j.semradonc.2013.11.004↗
  10. Role of radiation therapy in patients with resectable pancreatic cancer. Co-author PMID 21874833↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 5 shared papers, 2019–2023 · strength 0.51
  2. Brian G. Czito · 6 shared papers, 2011–2023 · strength 0.48
  3. Karyn A. Goodman · 4 shared papers, 2019–2025 · strength 0.46
  4. Sarah E. Hoffe · 4 shared papers, 2019–2023 · strength 0.39
  5. Manoop S. Bhutani · 3 shared papers, 2020–2025 · strength 0.36
  6. William Adrian Hall · 3 shared papers, 2019–2025 · strength 0.34
  7. Shalini Moningi · 3 shared papers, 2020–2023 · strength 0.33
  8. Matthew H. G. Katz · 2 shared papers, 2023–2025 · strength 0.28
  9. Eugene Jon Koay · 2 shared papers, 2023–2025 · strength 0.28
  10. Christopher G. Willett · 4 shared papers, 2011–2016 · strength 0.27
  11. Alok A. Khorana · 2 shared papers, 2019–2025 · strength 0.23
  12. Lauren Elizabeth Colbert · 2 shared papers, 2020–2023 · strength 0.21
  13. Jessica M. Frakes · 2 shared papers, 2020–2023 · strength 0.21
  14. Todd Anthony Aguilera · 2 shared papers, 2020–2023 · strength 0.21
  15. Rebecca S. Slack Tidwell · 2 shared papers, 2020–2023 · strength 0.21
  16. Cullen M. Taniguchi · 2 shared papers, 2020–2023 · strength 0.21
  17. Ying Yuan · 2 shared papers, 2020–2023 · strength 0.21
  18. Shubham Pant · 2 shared papers, 2020–2023 · strength 0.21
  19. Ching-Wei David Tzeng · 2 shared papers, 2020–2023 · strength 0.21
  20. Albert C. Koong · 2 shared papers, 2019–2021 · strength 0.18
  21. Davendra P. S. Sohal · 1 shared paper, 2025 · strength 0.15
  22. Andrew H. Ko · 1 shared paper, 2025 · strength 0.15
  23. Steve Walston · 1 shared paper, 2025 · strength 0.15
  24. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.15
  25. P. A. Philip · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.